Rodríguez Piñas, José MaríaRomero Lorca, AliciaGaibar Alonso, MaríaNovillo Villajos, ApoloniaRubio Alonso, MargaritaMalón, DiegoAntón Pascual, BeatrizCamacho Castañeda, Francisca InmaculadaCavanagh, MercedesLuján Rodríguez, David Ricardoet al.2025-10-212025-10-212025Jose María Rodríguez-Piñas, Alicia Romero-Lorca, María Gaibar, Apolonia Novillo, Margarita Rubio, Diego Malon, Beatriz Antón-Pascual, Francisca Inmaculada Camacho, Mercedes Cavanagh, David Ricardo Lujan Rodriguez, Ana Manuela Martín, Radia Khedaoui, Diana Moreno, Fernando Javier Pinedo, Macarena Boiza, Silvia García, Patricia Gómez, David Marrupe, Ana Fernández-Santander. Tumour SNPs associated with immune‑related hepatitis in patients with melanoma receiving immune checkpoint inhibitors. (2025). Biomedicines. 13(10), 2351. https://doi.org/10.3390/biomedicines131023512227-9059https://hdl.handle.net/11268/16410Immune checkpoint inhibitors (ICIs) have significantly improved survival rates for patients with metastatic melanoma. However, these treatments can lead to immune-related adverse events (irAEs), including hepatitis. This exploratory study sought to identify tumour single-nucleotide polymorphisms (SNPs) associated with the risk of ICI-induced hepatitis in melanomapatients. This exploratory study identifies candidate tumour SNPs as possible biomarkers to predict the risk of ICI-induced hepatitis, warranting their validation in larger patient cohorts.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/HepatitisPolimorfismo de Nucleótido SimpleMelanomajournal article10.3390/biomedicines13102351open accessCiencias médicasGenética humanaMedicina clínicaGoal 3: Ensure healthy lives and promote well-being for all at all agesGoal 4: Quality educationGoal 9: Build resilient infrastructure, promote sustainable industrialization and foster innovation